‘It’s just the beginning’ for pancreatic cancer’s long-awaited breakthroughnews2026-04-21T15:38:16+00:00April 21st, 2026|Endpoints News|
Novartis cuts two programs in cancer-related blood clotsnews2026-04-20T18:24:47+00:00April 20th, 2026|Endpoints News|
Gilead declines another Arcus option after Phase 3 TIGIT failnews2026-04-20T14:35:08+00:00April 20th, 2026|Endpoints News|
Nektar’s long-term mid-stage alopecia data fuel Phase 3 plansnews2026-04-20T11:32:12+00:00April 20th, 2026|Endpoints News|
Novo Nordisk’s sickle cell therapy hits in Phase 3, but data lag expectationsnews2026-04-20T10:46:34+00:00April 20th, 2026|Endpoints News|
#AACR26: KRAS drugmakers take another, better swing at lung cancernews2026-04-20T02:23:50+00:00April 20th, 2026|Endpoints News|
Three gene therapy pioneers just won the Breakthrough Prize. This is their storynews2026-04-18T23:13:44+00:00April 18th, 2026|Endpoints News|
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standoutsnews2026-04-17T15:38:49+00:00April 17th, 2026|Endpoints News|
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggestsnews2026-04-17T11:15:32+00:00April 17th, 2026|Endpoints News|
Cochrane review dismissing amyloid drugs draws immediate backlashnews2026-04-16T15:46:21+00:00April 16th, 2026|Endpoints News|
